Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience has entered into a $125 million revolving credit facility credit agreement, it said in a regulatory filing today.

The credit agreement, which took effect on May 24, replaces the Cincinnati-based company's loan and security agreement dated Aug. 1, 2007, and makes available to Meridian a revolving credit facility up to $125 million in aggregate amount. The credit facility expires in May 2024.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.